Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioMarin’s Bienaimé To Retire With Sales And Earnings Growth On Track

Executive Summary

Genentech CEO Alexander Hardy will succeed Jean-Jacques Bienaimé, who has led the rare disease specialist for 18 years. Gene therapy Roctavian has gotten off to a slow commercial start.

You may also be interested in...

BioMarin’s Next Chapter: ‘A Financial Growth Story’

The company presented its pipeline to investors during an R&D day, outlining expansion plans for Voxzogo and Roctavian as well as several early pipeline drugs.

Its Gene Therapy Roctavian Finally Approved With $2.9m Price, BioMarin Aims To Prove Doubters Wrong

BioMarin has finally brought its hemophilia A gene therapy Roctavian market and is determined prove naysayers wrong, but must work with its limitations and a confusing US label.

NYC’s Ambition: Be A Premier Biotech Hub

New York has its eye on becoming a premier biotech hub and is investing heavily in life sciences. Experts weighed in on the positives and drawbacks of the city for biotechs at a new innovation campus called Cure.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts